News
FOG-001 represents the first development candidate arising from FogPharma’s pioneering Helicon™ therapeutics, a new class of drugs capable of modulating protein-protein interactions that may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback